What Sucraid treats: main uses and benefits

Primary Use

Sucraid is an enzyme replacement therapy used to treat people who have a genetic condition known as congenital sucrase-isomaltase deficiency (CSID). This condition occurs when the body does not produce enough of the naturally occurring enzymes, sucrase and isomaltase, which are needed to break down and digest certain sugars.

How It Works

The active ingredient in Sucraid is sacrosidase. This enzyme functions as a replacement for the missing or deficient sucrase enzyme in the small intestine. When taken with meals or snacks, it helps break down sucrose (table sugar) into simpler sugars, such as glucose and fructose, which the body can then absorb.

Benefits in Symptom Management

By aiding in the digestion of sucrose, the use of this enzyme therapy can help manage the gastrointestinal symptoms associated with CSID. When sucrose remains undigested in the digestive tract, it can cause various forms of discomfort. Effective breakdown of these sugars may lead to a reduction in:

• Abdominal pain and cramping
• Bloating and gas
• Watery diarrhea
• Nausea

Nutritional Impact

For individuals with CSID, the inability to digest sugar often requires strict dietary restrictions. The primary benefit of treatment is the improved ability to tolerate foods containing sucrose. This can lead to better overall nutrient absorption and may help support healthy weight maintenance or growth in children who have previously struggled with malabsorption.

Regulatory References

1. FDA DailyMed label for Sucraid

Eligibility Map: Who can and cannot use Sucraid — Official Regulatory Information

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adult and pediatric patients 5 months of age and older with genetically determined sucrase deficiency (part of Congenital Sucrase-Isomaltase Deficiency, CSID).
Populations for whom use is not recommended (if applicable)	Use has not been established in patients with secondary (acquired) sucrase deficiency.
Populations for whom use is contraindicated	Patients with known hypersensitivity to yeast, yeast products, glycerin (glycerol), or papain.
Age-related eligibility rules	Safety and efficacy are established for patients aged 5 months and older. Safety and efficacy are not established for children younger than 5 months. Clinical trials did not include patients 65 years of age and older.
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Should be given only if clearly needed. Lactation: Adverse effects on a nursing infant are not expected.
Eligibility-related restrictions	Patients with Diabetes Mellitus or a history of Asthma/severe allergies require caution upon use.

---

Eligibility Classifications (High-Level)

Category	Official Regulatory Classification
Eligibility severity classification (as defined in official documents)	Contraindicated (for hypersensitivity); Established (for CSID patients ge 5 months); Use Not Established (for acquired deficiency/infants <5 months).
Regulatory basis (EMA / FDA / etc.)	United States FDA Prescribing Information.

---

Connection to the overall eligibility profile:

Official regulatory documents strictly define the eligible population as those with the specific genetic diagnosis of CSID, starting at a minimum age of 5 months. They also establish an absolute contraindication for hypersensitivity to the components (yeast, glycerin, papain). The labeling requires caution for patients with diabetes or severe allergies and notes that the effects of the medicine have not been evaluated in patients with acquired sucrase deficiency.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The official regulatory documentation for sacrosidase (Sucraid) indicates that traditional drug-drug and drug-food interactions are not expected or have not been reported (Source 1.7, 3.7). The profile is instead structured around functional and physical constraints that affect the enzyme's activity or the resulting systemic sugar load.

Interaction Category	Specific Restriction or Constraint
Physical/Chemical Restrictions	Must not be mixed with hot or warm liquids (reduces enzyme potency). Must not be mixed with acidic liquids (e.g., fruit juice), as high acidity reduces enzyme activity (Source 1.2, 1.7, 3.7).
Physiologic Consequences	The enzyme’s function increases the absorption of glucose and fructose, requiring specific monitoring in certain populations (Source 1.7).
Contraindicated Combinations	Combinations are formally contraindicated in patients with known hypersensitivity to the drug’s components, including yeast, yeast products, glycerin, or the manufacturing byproduct papain (Source 1.7, 3.7).

Population-Specific Interaction Constraint

Due to the increased systemic absorption of glucose and fructose caused by the enzyme’s action, a population-specific constraint is noted for individuals with Diabetes Mellitus. These patients require careful blood glucose monitoring, and their antidiabetic regimen may need adjustment, which constitutes a mandatory interaction consideration (Source 1.7, 3.7). Co-administration with oral alpha-glucosidase inhibitors may also present a pharmacodynamic conflict (Source 3.1).

The active component of Sucraid is sacrosidase, a synthetic enzyme classified as an enzyme replacement therapy. Its mechanism is localized entirely within the gastrointestinal lumen, specifically the small intestine, and does not involve systemic absorption or intracellular pathways.

---

Enzyme Replacement-Mediated Hydrolysis

Sacrosidase acts as an exogenous sucrase, directly engaging in enzyme-mediated hydrolysis within the small intestine. It binds to and catalyzes the breakdown of the dietary disaccharide, sucrose (table sugar). This action initiates the critical mechanistic cascade of carbohydrate digestion, modifying the initial molecular step for this substrate.

---

Monosaccharide Generation and Gut Regulation

This process modulates the pathway associated with carbohydrate assimilation. Sacrosidase splits sucrose into its absorbable component monosaccharides: glucose and fructose. This conversion facilitates their uptake by the small intestine. Consequently, this action reduces the concentration of unhydrolyzed sucrose reaching the colon, thereby diminishing substrate availability for bacterial fermentation and lowering the presence of osmotically active and fermentation-derived products in the distal intestine.

The administration of Sucraid (sacrosidase) follows a fixed oral protocol designed for continuous replacement therapy.

---

Dosing and Frequency

Administration is tied directly to the consumption of food, requiring a dose to be taken with every meal or snack. The standard regimen dictates a weight-dependent volume, with the 15 kg body weight threshold applying to all patients five months of age and older.

Patient Weight	Recommended Dose Volume
Over 15 kg	2 mL (17,000 IU) per meal or snack
15 kg and under	1 mL (8,500 IU) per meal or snack

The required dose is administered in a divided manner: approximately half of the solution is taken at the beginning of the meal or snack, and the remaining half is taken during the meal or snack.

---

Preparation and Constraints

Prior to oral consumption, the solution must be diluted with 4 oz to 8 oz of cold or room temperature water, milk, or infant formula. It is prohibited to mix or consume Sucraid with fruit juices or warm/hot liquids, as heat or acidity can impact the enzyme’s stability. The dose must be measured using the provided measuring scoop, and the diluted solution must be consumed immediately.

Research Evidence / Overview of Studies for Sacrosidase (Sucraid)

This section provides a transparent overview of the research that has examined sacrosidase, focusing only on the structure and findings of the clinical studies used in its regulatory evaluation. The evidence describes group patterns and what has been observed so far, but does not determine whether an individual will respond similarly.

---

Evidence for Use in Genetically Determined Sucrase Deficiency

The research has explored the use of sacrosidase in individuals with Congenital Sucrase-Isomaltase Deficiency (CSID), which is a condition characterized by fluctuating or episodic manifestations resulting from a lack of the natural sucrase enzyme.

The core research examined this medicine in controlled clinical trials, which often featured a dose-response design to help examine dose-response patterns and determine specific enzyme concentrations. These trials were applied in studies examining patient-reported experiences of physical discomfort and outcomes related to systemic imbalance. Following these initial controlled trials, longer-term longitudinal observational studies were conducted, tracking patients for extended periods after they began using the medicine.

Findings describe patterns observed in the studies where reports of being symptom-free for a defined period were observed more frequently in the study groups. Additionally, research monitored changes in stool characteristics, and research described measurements showing a shift toward fewer watery stools and more formed stools in the observed populations. Research also explored objective changes in the sucrose hydrogen breath test results, which are markers used to track the body’s response to dietary sucrose. These research findings contribute to the broader evidence landscape for this specific, genetically determined condition.

---

Understanding Long-Term Outcomes and Follow-Up

Research also explored the outcomes over extended time intervals beyond the initial short-term trials. These observational settings evaluating daily-life functioning were observed in studies that tracked patient responses for periods up to 54 months (over four years).

These long-term studies report how symptoms evolved in the observed populations and were used in research exploring how symptoms change over time in patients continuing the treatment approach. However, while some data show patterns related to sustained observations of symptom levels, the long-term effects are not fully established and data for long-term outcomes remain limited compared to short-term data.

---

What Remains Uncertain in the Research Landscape

The research provides context but not individual predictions and highlights several areas where the evidence is limited or where more research is still needed.

The sample sizes were modest in the initial controlled trials that were submitted for regulatory review, meaning the results apply only to the populations studied and do not reflect the diverse broader population. Crucially, the research does not include studies evaluating the medicine's use for secondary (acquired) sucrase deficiency that may be caused by other underlying conditions. The existing evidence is only for the inherited, or genetically determined, form of the condition.

Furthermore, the enzyme replacement in the medicine targets sucrase only, and does not address the deficient isomaltase enzyme, which is also a component of the CSID condition. This means that research suggests the potential for continued need for dietary management of starches for some patients, indicating that the medicine does not provide full enzyme replacement for all dietary elements processed by the natural sucrase-isomaltase complex.

Key Studies & References

1. Sacrosidase Therapy for Congenital Sucrase-Isomaltase Deficiency (Treem et al., 1999)
2. Evaluation of Sacrosidase Efficacy in Patients with Congenital Sucrase-Isomaltase Deficiency (Clinical Trial Summary OMC-SUC-3)

Official Storage and Disposal Requirements

Sucraid (sacrosidase) oral solution must be refrigerated at a temperature between 36 F and 46 F (2 C and 8 C). It is mandatory to protect the solution from freezing, heat, and light to maintain its stability.

Storage Constraint	Requirement
Temperature	Refrigerate; Do not freeze.
In-Use Stability	Discard the multiple-dose bottle 4 weeks after first opening.
Protection	Protect from heat and light.
Temporary Use	Single-use containers may be stored at room temperature (59 F to 77 F) for up to 72 hours for travel.

For proper handling, the measuring scoop should be rinsed with water after each use. All unused, outdated, or time-expired medicine must be discarded. The official labeling directs patients to keep Sucraid out of the reach of children and to consult a healthcare professional for specific disposal instructions.